Background: The aim of this research was to assess the impact of treatment with Orlistat 120 mg three times daily on serum leptin levels, weight loss, glycemic control, and cardiovascular risk factors involved in the metabolic syndrome.
Methods: A 3-month open-labeled prospective study was conducted on 40 patients with the clinical features of the metabolic syndrome divided into two groups—with and without type 2 diabetes mellitus. Twenty type 2 diabetic obese patients (group A) were studied, with BMI of 35.4 ± 0.9 kg/m2, as were 20 obese patients without diabetes (group B), with BMI of 36.2 ± 0.7 kg/m2. Weight, serum leptin levels, insulin resistance, and cardiovascular risk factors were measured at baseline and at the end of each month.
Results: Patients reduced weight at 8.5 ± 2.3 kg for men and 5.7 ± 2.6 kg for women in group A against 7.9 ± 1.9 kg for men and 5.6 ± 2.0 kg for women in group B. Plasma leptin levels decreased at 4.5 ± 1.9 ng/mL for men and 1.9 ± 0.9 ng/mL for women in group A against 3.8 ± 2.0 ng/mL for men and 2.8 ± 1.4 ng/mL for women in group B. The level of insulin resistance measured with HOMA-IR decreased from 4.54 ± 2.35 to 2.69 ± 0.86 in group A against 3.98 ± 1.89 to 2.87 ± 0.93 in group B. In the lipid parameters, the highest decrease was found in triglycerides levels: 6.1 ± 2.3 mmol/L for men and 3.5 ± 2.6 mmol/L for women in group A against 2.1 ± 1.9 mmol/L for men and 1.8 ± 0.7 mmol/L for women in group B (all p < 0.05).
Conclusions:
Orlistat beneficially enhances weight loss, contributing to a decrease of serum leptin, insulin resistance level, and cardiovascular risk factors in both groups. An additional beneficial pleotropic effect of Orlistat could be proposed through a reduction of plasma leptin and lipid levels.
